58 research outputs found
Crack path and fracture analysis in FSW of small diameter 6082-T6 aluminium tubes under tension-torsion loading
This paper reports part of the work done in a research project aimed at developing an optimised process to join 38. mm diameter tubes of 6082-T6 aluminium alloy using friction stir welding (FSW), and then to determine the fatigue performance under tension, torsion and tension-torsion loading conditions. The final outcome of the project is intended to be guidance for fatigue design of small diameter aluminium tubes joined by FSW, and this paper presents information on crack path and defects under the various loading conditions. Crack path analysis was performed using both low magnification stereo microscopy and scanning electron microscopy, in order to identify crack initiation sites, the direction of crack propagation and the interrelated influence of microstructure and weld geometry on the crack initiation path
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
Introduction: Estrogen receptor-alpha (ER-alpha) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-beta) in various breast cancer risk groups treated with different therapeutic regimens is available. In particular, there are no data concerning ER-beta distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN). Methods: We conducted an observational prospective study using immunohistochemistry to evaluate ER-beta expression in 936 breast carcinomas. Associations with conventional biopathological factors and with molecular subtypes were analyzed by multiple correspondence analysis (MCA), while univariate and multivariate Cox regression analysis and classification and regression tree analysis were applied to determine the impact of ER-beta on disease-free survival in the 728 patients with complete follow-up data. Results: ER-beta evenly distributes (55.5%) across the four molecular breast cancer subtypes, confirming the lack of correlation between ER-beta and classical prognosticators. However, the relationships among the biopathological factors, analyzed by MCA, showed that ER-beta positivity is located in the quadrant containing more aggressive phenotypes such as HER2 and TN or ER-alpha/PgR/Bcl2- tumors. Kaplan-Meier curves and Cox regression analysis identified ER-beta as a significant discriminating factor for disease-free survival both in the node-negative LA (P = 0.02) subgroup, where it is predictive of response to HT, and in the node-positive LB (P = 0.04) group, where, in association with PgR negativity, it conveys a higher risk of relapse. Conclusion: Our data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-beta positivity appears to be a biomarker related to a more aggressive clinical course. In this context, further investigations are necessary to better assess the role of the different ER-beta isoforms
Bringing oncoâinnovation to Europeâs healthcare systems. The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine
Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, preâeminently in many cancers, but also in an everâwider range of conditionsâ notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by countryârelated heterogeneity, data deficiencies, and lack of policy alignment on standards, approvalâand the role of realâworld evidence in the processâand reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europeâs industrial competitiveness and innovation require an appropriate policy frameworkâstarting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients
Bringing onco-innovation to Europeâs healthcare systems: the potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine
International audienceRapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditionsânotably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approvalâand the role of real-world evidence in the processâand reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europeâs industrial competitiveness and innovation require an appropriate policy frameworkâstarting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients
p27 Deficiency Cooperates with Bcl-2 but Not Bax to Promote T-Cell Lymphoma
The effect of Bcl-2 on oncogenesis is complex and expression may either delay or accelerate oncogenesis. The pro-oncogenic activity is attributed to its well characterized anti-apoptotic function while the anti-oncogenic function has been attributed to its inhibition of cellular proliferation. Recent studies demonstrate that p27 may mediate the effects of Bcl-2 on cellular proliferation. We hypothesized that p27 may suppress tumor formation by Bcl-2 family members. To test this hypothesis, cell cycle inhibition and lymphoma development were examined in Lck-Bcl-2 and Lck-Bax38/1 transgenic mice deficient in p27. Strikingly, p27 deficiency synergistically cooperates with Bcl-2 to increase T cell hyperplasia and development of spontaneous T cell lymphomas. Within 1 year, >90% of these mice had developed thymic T cell lymphomas. This high penetrance contrasts with a one year incidence of <5% of thymic lymphoma in Lck-Bcl-2 or p27 â/â mice alone. In contrast, p27 deficiency had no effect on tumor formation in Lck-Bax38/1 transgenic mice, another model of T cell lymphoma. Histologically the lymphomas in p27 â/â Lck-Bcl-2 mice are lymphoblastic and frequently involve multiple organs suggesting an aggressive phenotype. Interestingly, in mature splenic T cells, Bcl-2 largely retains its anti-proliferative function even in the absence of p27. T cells from p27 â/â Lck-Bcl-2 mice show delayed kinetics of CDK2 Thr-160 phosphorylation. This delay is associated with a delay in the up regulation of both Cyclin D2 and D3. These data demonstrate a complex relationship between the Bcl-2 family, cellular proliferation, and oncogenesis and demonstrate that p27 up-regulation is not singularly important in the proliferative delay observed in T cells expressing Bcl-2 family members. Nonetheless, the results indicate that p27 is a critical tumor suppressor in the context of Bcl-2 expression
Bringing oncoâinnovation to Europeâs healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine
Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, preâeminently in many cancers, but also in an everâwider range of conditionsâ notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by countryârelated heterogeneity, data deficiencies, and lack of policy alignment on standards, approvalâand the role of realâworld evidence in the processâand reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europeâs industrial competitiveness and innovation require an appropriate policy frameworkâstarting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients
Dehydrogenative Azolation of Arenes in a Microflow Electrochemical Reactor
The electrochemical synthesis of aryl azoles was performed for the first time in a microflow reactor. The reaction relies on the anodic oxidation of the arene partners making these substrates susceptible for C-H functionalization with azoles, thus requiring no homogeneous transition-metal-based catalysts. The synthetic protocol benefits from the implementation of a microflow setup, leading to shorter residence times (10 min), compared to previously reported batch systems. Various azolated compounds (22 examples) are obtained in good to excellent yields
I don't understand what it's saying The need for and provision of translated written information and materials
Report prepared by the Migrant Support Unit of the LVSC and funded by the London Boroughs Grants CommitteeAvailable from British Library Document Supply Centre- DSC:q91/19472(I don't) / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo
Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment.
Abstract:
Background
The aim of this study was to evaluate whether body mass index (BMI)
is independently correlated with plasma aldosterone concentration
(PAC) in treated essential hypertensive patients, and whether the
relationship between BMI and high blood pressure (BP) can be
partially mediated by PAC despite reninâangiotensinâaldosterone
system blockade.
Methods
This study used a cross-sectional design and included 295
consecutive essential hypertensive patients referred to our centre
for uncontrolled BP despite stable antihypertensive treatment
for at least 6 months. The main exclusion criteria were age >65
years; glomerular filtration rate <30 ml/min; and therapy with
mineralocorticoid receptor antagonists, direct renin inhibitors,
amiloride or oral contraceptives.
Results
Higher levels of obesity showed a significantly higher mean PAC with
a steep nonlinear increase in patients with BMI â„35 kg/m2. Class 2 and
3 obese patients had a higher mean PAC than nonobese and class 1
obese patients, even in patients under stable treatment with either
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin
receptor blockers (ARBs). In a stepwise multiple linear regression
model, only log of plasma renin activity (PRA), mean blood pressure
(MBP), and class 2 and 3 obesity showed an independent correlation
with PAC. In the same model applied to patients treated with ACEIs
or ARBs, only logPRA and class 2 and 3 obesity showed a direct
correlation with PAC.
Conclusions
In treated essential hypertensive patients, a BMI â„35 kg/m2 is
independently, albeit modestly, correlated with PAC. The correlation
between BMI â„35 kg/m2 and PAC holds true even in ACEI/ARBtreated
patients. Further study is required to determine whether the
association of obesity with BP is mediated by PAC in hypertensive
patients on stable therapy with ACEIs or ARBs
- âŠ